An FDA official involved in scrutinizing the safety of antidepressants, COVID-19 vaccines, and other widely used therapies has been removed from her role leading the agency's drug program.
Tracy Beth Hoeg, MD, PhD, will be replaced as FDA acting drug center director by Mike Davis, MD, PhD, who has been serving as deputy director, according to an email sent to agency staff Friday that was obtained by the Associated Press.
Hoeg said in a social media post late Friday that she was "fired," from the agency, adding: "I learned so much and leave with no regrets."
Hoeg's departure is the latest in an ongoing shake-up at the powerful regulatory agency. FDA Commissioner Marty Makary, MD, resigned earlier in the week, and Vinay Prasad, MD, MPH, the agency's vaccine and biotech chief, stepped down last month following intense criticism from drugmakers, patients, and investors.
The agency also announced Friday that Karim Mikhail would take over as acting director of the vaccines center. Mikhail, a longtime pharmaceutical executive, was hired by Makary last spring.
